Download this Press Release as a PDF
IngenOx Therapeutics, the Oxford biopharma company, focused on developing novel cancer therapeutics, announced today that its Chief Medical Officer, Prof. David Kerr has been awarded the China Friendship Medal.
Ingenox is pleased to report that its Chief Medical Officer, Professor David Kerr CBE was awarded the China Friendship Medal, the highest civilian honour that China can offer to non-nationals.
The Friendship Medal is bestowed on foreign nationals who have made outstanding contributions to the promotion of exchange and co-operation between China and other countries.
The medal was presented recently at the Great Hall of the People, Beijing, China.
Prof David Kerr at the Great Hall of the People, Beijing
Professor Kerr CBE MD DSc FRCP FRGCP FACP FESMO FMedSci is a British medical oncologist with over 40 years experience in cancer research. His primary interest is the treatment and management of bowel cancer. He is currently Professor of Cancer Medicine at the University of Oxford, and holds the additional positions of Honorary Consultant Medical Oncologist, Oxford Cancer Centre; Co-Director, Oxford-Sichuan Gastrointestinal Cancer Centre; and Honorary Professor, University of Oslo. In the commercial sector, he has co-founded companies such as Cobra Therapeutics, Oxford Cancer Biomarkers, Celleron Therapeutics, SynOx Therapeutics, and IngenOx Therapeutics.
David Kerr, CMO of IngenOx, and Professor of Cancer Medicine at the University of Oxford commented:
“This is a great honour, and reflects the strength of my association with many leading Chinese cancer experts and their Universities. I believe firmly that international collaboration, bringing together some of the greatest scientists and clinicians in the world, is the only way that our academic community can best serve the community of cancer patients. In a small way, this may help to strengthen health diplomatic ties between our nations.”
Nick La Thangue, CEO of IngenOx, and Professor of Cancer Biology at the University of Oxford commented:
This award recognises the many years that David has spent supporting senior Chinese oncologists and training young scientists in Oxford. China is an important clinical trials partner for Ingenox as we take our lead compound, zabadinostat into clinical trials in refractory hepatocellular cancer, working with colleagues in the Chinese University of Hong Kong.”
NOTES:
About IngenOx Therapeutics
IngenOx Therapeutics is a bio-pharmaceutical company focused on delivering new precision medicine drugs and vaccines to treat the most difficult cancers, often referred to as cold tumours. It is a spinout from the University of Oxford, and is located in the Oxford Science Park, UK. Its pipeline comprises early to late-stage products that work in different ways to activate the immune response against cold tumours, which are generally poorly recognised by the immune system.
The company’s approach seeks to align the right drug with the right patient enabling a targeted precision medicine approach to cancer therapy. It has also built a proprietary platform around re-educating the body’s immune system to recognise and destroy tumours. The assets in its pipeline have displayed convincing clinical benefits to late-stage cancer patients through disease control, tumour shrinkage, reduced side effects, and extended survival times.
The company has secured multiple rounds of investment and has numerous license and partnership agreements in place.
For more information see www.ingenox.com